Japan vs Marshall Islands: Prevalence rate of hypertension in adults aged 30-79
Japan
31.4
in 2019
Marshall Islands
31.9
in 2019
Japan rank
152nd
Marshall Islands rank
149th
Prevalence rate of hypertension in adults aged 30-79 over time
- Japan
- Marshall Islands
How they compare
Marshall Islands currently reports 31.9 against 31.4 in Japan, a difference of 0.5.
The two have swapped places 1 time across 30 shared years of data; in 1990 it was Japan ahead.
Japan ranks 152nd and Marshall Islands ranks 149th of 194 countries.
Japan has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Japan | Marshall Islands | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 36.88 | 28.58 | 8.3 | Japan |
| 2000s | 33.15 | 28.82 | 4.33 | Japan |
| 2010s | 32.01 | 31.19 | 0.82 | Japan |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence rate of hypertension in adults aged 30-79, Japan or Marshall Islands?
- Marshall Islands, at 31.9 against 31.4 in Japan as of 2019.
- What is the difference in prevalence rate of hypertension in adults aged 30-79 between Japan and Marshall Islands?
- 0.5, with Marshall Islands ahead.
- How many years of comparable data are there for Japan and Marshall Islands?
- 30 years are reported by both, from 1990 to 2019.
- How do Japan and Marshall Islands rank globally for prevalence rate of hypertension in adults aged 30-79?
- Japan ranks 152nd and Marshall Islands ranks 149th of 194 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Prevalence rate of hypertension in adults aged 30-79. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Estimated share of the population with hypertension, based on population representative surveys and statistical modeling. Hypertension is a risk factor for chronic complications, including cardiovascular disease, and premature death.